On test day, “oncogene vs tumor suppressor” questions don’t miss—they’re everywhere, and they’re rarely asked as pure recall. The trick is that every answer choice is a mini–board review: if you can explain why each distractor is wrong, you’ll stop getting baited by buzzwords like “two-hit,” “dominant,” “fusion protein,” and “growth factor receptor.”
Tag: Pathology > General Pathology
The Clinical Vignette (Q-bank style)
A 62-year-old man with a 45–pack-year smoking history presents with weight loss and cough. Imaging reveals a central lung mass. Biopsy shows small blue cells with nuclear molding. Immunohistochemistry is positive for synaptophysin and chromogranin. Molecular testing demonstrates a mutation in a gene encoding a GTPase involved in signal transduction that results in constitutive activation of downstream MAP kinase signaling.
Which of the following best describes the genetics of this mutation?
A. Requires loss of both alleles to drive tumorigenesis
B. Gain-of-function mutation acting in a dominant fashion at the cellular level
C. Inactivation results in failure of DNA mismatch repair
D. A chromosomal translocation creates a fusion protein with constitutive tyrosine kinase activity
E. Increased gene dosage due to amplification leads to overexpression of a cell cycle regulator
Step-by-Step: What the Stem Is Really Testing
The stem tells you:
- Small cell lung carcinoma (SCLC): smoking association, central mass, neuroendocrine markers
- Mutation in a GTPase involved in signal transduction with constitutive activation of MAPK
- That screams RAS (KRAS/HRAS/NRAS)
- Constitutive activation = gain-of-function
- Gain-of-function mutations in proto-oncogenes become oncogenes
- Classic USMLE phrasing: dominant at the cellular level
Correct Answer: B. Gain-of-function mutation acting in a dominant fashion at the cellular level
Why B is correct (Oncogene logic)
Proto-oncogenes normally promote growth/survival in a controlled way. When mutated/overexpressed, they become oncogenes that push proliferation.
Key USMLE framing:
- Oncogenes = gain-of-function
- One “hit” is enough (dominant effect within the cell)
- The patient can be heterozygous for the mutant allele in that tumor clone and still have the phenotype.
High-yield RAS facts
- RAS is a membrane-associated GTPase
- Normal: toggles between inactive GDP-bound and active GTP-bound states
- Mutation: often decreased GTPase activity → stuck “on” (GTP-bound) → persistent signaling through:
- MAPK/ERK pathway (proliferation)
- PI3K/AKT pathway (survival)
Classic associations
- KRAS: pancreatic adenocarcinoma, colorectal carcinoma, lung adenocarcinoma (also seen broadly)
Even though this stem describes SCLC clinically, the genetics clue is the real target: oncogene mechanics.
The Big Picture: Oncogenes vs Tumor Suppressors (Boards Framework)
| Feature | Oncogenes | Tumor suppressor genes |
|---|---|---|
| Normal role | Promote growth/survival (regulated) | Restrain growth, repair DNA, induce apoptosis |
| Pathogenic change | Gain-of-function | Loss-of-function |
| Hits needed | 1 (dominant at cellular level) | Usually 2 (two-hit hypothesis) |
| Common mechanisms | Point mutation, amplification, translocation | Deletion, nonsense/frameshift, promoter methylation |
| Examples | RAS, MYC, HER2, BCR-ABL | TP53, RB, APC, BRCA1/2, PTEN |
Now Destroy the Distractors (This Is Where Your Score Jumps)
A. Requires loss of both alleles to drive tumorigenesis
This is describing a tumor suppressor gene (two-hit hypothesis).
Why it’s wrong here:
- The stem says constitutive activation of signaling (gain-of-function).
- Tumor suppressor loss typically removes brakes (e.g., RB, TP53), not permanently activates a pathway through a GTPase.
High-yield examples of “two-hit” tumor suppressors
- RB (retinoblastoma, osteosarcoma)
- TP53 (Li-Fraumeni; many sporadic cancers)
- APC (FAP → colon cancer)
- BRCA1/2 (DNA repair via homologous recombination)
Board nuance: Not every tumor suppressor is strictly “two-hit” in practice (haploinsufficiency exists), but USMLE classic framing = two hits.
C. Inactivation results in failure of DNA mismatch repair
This points to Lynch syndrome (HNPCC) due to mismatch repair gene defects:
- MLH1, MSH2, MSH6, PMS2
- Leads to microsatellite instability
Why it’s wrong here:
- Mismatch repair failure increases mutation rate; it does not specifically create a constitutively active MAPK signal.
- MMR genes behave like tumor suppressors (loss-of-function).
High-yield associated cancers
- Colorectal (often right-sided), endometrial, ovarian, gastric
Clue words: “microsatellite instability,” “sessile serrated,” “multiple cancers,” “young age.”
D. A chromosomal translocation creates a fusion protein with constitutive tyrosine kinase activity
This describes classic fusion oncogenes, especially:
- BCR-ABL t(9;22) → constitutive tyrosine kinase → CML, some ALL
Why it’s wrong here:
- The stem specifically says the gene encodes a GTPase (RAS), not a tyrosine kinase.
- Translocations that create fusion TKs are common in leukemias/lymphomas, not the typical “RAS stuck on” mechanism.
Other translocation oncogene hits
- t(14;18) BCL2 (follicular lymphoma) → anti-apoptosis (not TK)
- t(8;14) MYC (Burkitt) → transcription factor dysregulation
Q-bank pattern: If they want BCR-ABL, they usually give:
- very high WBC, basophilia, low leukocyte alkaline phosphatase, splenomegaly.
E. Increased gene dosage due to amplification leads to overexpression of a cell cycle regulator
This is gene amplification → oncogene overexpression.
Good examples:
- HER2/ERBB2 amplification (breast cancer)
- MYC amplification (various)
- MDM2 amplification (inhibits p53)
- Cyclin D (CCND1) overexpression (mantle cell lymphoma classically via t(11;14), not amplification)
Why it’s wrong here:
- Amplification is plausible for oncogenes—but the stem already told you the protein is a GTPase with constitutive activation, which is most consistent with a point mutation in RAS, not amplification of a cyclin regulator.
Test-taking pearl: When the stem names the type of protein (GTPase, transcription factor, receptor TK), your job is to match the mechanism.
High-Yield Mini-Atlas: “If You See X, Think Y”
Oncogene mechanisms (one-hit, GOF)
- Point mutation → RAS (signal transduction)
- Amplification → HER2, MYC
- Translocation:
- Fusion protein → BCR-ABL
- Promoter swapping → MYC t(8;14) (Ig heavy chain promoter)
Tumor suppressor mechanisms (two-hit, LOF)
- RB: G1→S checkpoint brake (E2F regulation)
- TP53: DNA damage response (“guardian of the genome”)
- Activates p21 to inhibit cyclin-CDK complexes
- Can induce apoptosis (BAX, PUMA)
- APC: regulates β-catenin in Wnt signaling
- BRCA1/2: homologous recombination DNA repair
- PTEN: inhibits PI3K/AKT signaling (growth suppression)
Common Traps and How to Avoid Them
Trap 1: Confusing “dominant at cellular level” with inheritance pattern
- Oncogenes: dominant at the cellular level (one mutant allele drives growth in that cell)
- Cancer syndromes: often inherited as “autosomal dominant predisposition,” but the actual tumor typically still requires additional events.
Trap 2: Thinking “two-hit” automatically means “familial”
- Sporadic cancers can still lose both alleles via:
- deletion, point mutation, methylation, loss of heterozygosity
Trap 3: Overweighting the cancer type instead of the molecular clue
The stem’s histology may set the scene, but the protein function (GTPase vs mismatch repair vs tyrosine kinase) is the real discriminator.
Rapid Review (What You Should Be Able to Say Out Loud)
- RAS is an oncogene when mutated → gain-of-function → constitutive MAPK signaling → dominant at cellular level.
- Tumor suppressors require loss of function, typically both alleles.
- Mismatch repair loss → microsatellite instability (Lynch).
- Fusion TK via translocation → BCR-ABL (CML/ALL).
- Amplification → HER2/MYC (overexpression).